{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:48:40Z","timestamp":1790171320193,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T00:00:00Z","timestamp":1561680000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T00:00:00Z","timestamp":1561680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministero della Salute Italian Gouvernment","award":["Funds for Institutional research 2016"],"award-info":[{"award-number":["Funds for Institutional research 2016"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5829-4","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T15:02:57Z","timestamp":1561734177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["BRCA germline mutation test for all woman with ovarian cancer?"],"prefix":"10.1186","volume":"19","author":[{"given":"A. V.","family":"Paradiso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Digennaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Patruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"De Summa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tommasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Berindan-Neagoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,28]]},"reference":[{"key":"5829_CR1","doi-asserted-by":"crossref","unstructured":"Auguste A, Leary A. Abnormalities of DNA repair and gynecological cancers. Bull Cancer. 2017;104(11):971\u2013980.","DOI":"10.1016\/j.bulcan.2017.09.007"},{"issue":"11","key":"5829_CR2","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105(11):812\u201322.","journal-title":"J Natl Cancer Inst"},{"key":"5829_CR3","unstructured":"https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf"},{"issue":"1","key":"5829_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/GCO.0000000000000142","volume":"27","author":"JL Profato","year":"2015","unstructured":"Profato JL, Arun BK. Genetic risk assessment for breast and gynecological malignancies. Curr Opin Obstet Gynecol. 2015;27(1):1\u20135.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"11","key":"5829_CR5","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/nm.3369","volume":"19","author":"CJ Lord","year":"2013","unstructured":"Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med. 2013;19(11):1381\u20138.","journal-title":"Nat Med"},{"key":"5829_CR6","unstructured":"https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm533891.htm"},{"key":"5829_CR7","unstructured":"http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003726\/human_med_001831.jsp&mid=WC0b01ac058001d124\n                    \n                  ."},{"issue":"5","key":"5829_CR8","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nrclinonc.2016.191","volume":"14","author":"A George","year":"2017","unstructured":"George A, Kaye S, Banerjee S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Clin Oncol. 2017;14(5):284\u201396.","journal-title":"Nat Rev Clin Oncol"},{"key":"5829_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejca.2016.03.009","volume":"61","author":"M Arts-de Jong","year":"2016","unstructured":"Arts-de Jong M, de Bock GH, van Asperen CJ, Mourits MJ, de Hullu JA, Kets CM. Germline BRCA1\/2 mutation testing is indicated in every patient with epithelial ovarian cancer: a systematic review. Eur J Cancer. 2016;61:137\u201345.","journal-title":"Eur J Cancer"},{"issue":"15\u201316","key":"5829_CR10","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s00508-015-0814-7","volume":"127","author":"C Marth","year":"2015","unstructured":"Marth C, Hubalek M, Petru E, Polterauer S, Reinthaller A, Schauer C, et al. AGO Austria recommendations for genetic testing of patients with ovarian cancer. Wien Klin Wochenschr. 2015;127(15\u201316):652\u20134.","journal-title":"Wien Klin Wochenschr"},{"issue":"18","key":"5829_CR11","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.2217\/fon-2016-0189","volume":"12","author":"C Pinto","year":"2016","unstructured":"Pinto C, Bella MA, Capoluongo E, Carrera P, Clemente C, Colombo N, et al. Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients. Future Oncol. 2016;12(18):2071\u20135.","journal-title":"Future Oncol"},{"key":"5829_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejca.2016.10.006","volume":"69","author":"I Vergote","year":"2016","unstructured":"Vergote I, Banerjee S, Gerdes AM, van Asperen C, Marth C, Vaz F, et al. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. Eur J Cancer. 2016;69:127\u201334.","journal-title":"Eur J Cancer"},{"key":"5829_CR13","doi-asserted-by":"publisher","first-page":"g1200","DOI":"10.1136\/bmj.g1200","volume":"348","author":"S Arie","year":"2014","unstructured":"Arie S. Routine testing for women with ovarian cancer. BMJ. 2014;348:g1200.","journal-title":"BMJ"},{"key":"5829_CR14","doi-asserted-by":"publisher","first-page":"f5664","DOI":"10.1136\/bmj.f5664","volume":"347","author":"J Wise","year":"2013","unstructured":"Wise J. Charity calls for routine BRCA testing of ovarian cancer patients. BMJ. 2013;347:f5664.","journal-title":"BMJ."},{"issue":"18","key":"5829_CR15","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1001\/jama.2016.2640","volume":"315","author":"DA Levine","year":"2016","unstructured":"Levine DA, Karlan BY, Strauss JF. Evolving approaches in research and Care for Ovarian Cancers: a report from the National Academies of sciences, engineering, and medicine. JAMA. 2016;315(18):1943\u20134.","journal-title":"JAMA."},{"key":"5829_CR16","unstructured":"NHS. Developing Testing Criteria for Familial Breast and Ovarian Cancer: Incorporating NICE Guidelines. UK Genetic Testing Network. Meeting report from Chandos House, London (2014). Available at \n                    Http:\/\/kgtn.nhs.uk\/fileadmin\/uploads\/ukgtn\/Documents\/Resources\/Library\/Reports_Guidelines\/UKGTN%20breast%20cancer%20Final%20161014.pdf\n                    \n                  ."},{"issue":"17","key":"5829_CR17","doi-asserted-by":"publisher","first-page":"4703","DOI":"10.1093\/hmg\/ddu172","volume":"23","author":"H Song","year":"2014","unstructured":"Song H, Cicek MS, Dicks E, Harrington P, Ramus SJ, Cunningham JM, et al. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Genet. 2014;23(17):4703\u20139.","journal-title":"Hum Mol Genet"},{"key":"5829_CR18","unstructured":"https:\/\/CRAN.R-project.org"},{"issue":"3","key":"5829_CR19","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1198\/106186006X133933","volume":"15","author":"T Hothorn","year":"2006","unstructured":"Hothorn T, Hornik K, Zeileis A. Unbiased recursive partitioning: a conditional inference framework. J Comput Graph Stat. 2006;15(3):651\u201374.","journal-title":"J Comput Graph Stat"},{"issue":"21","key":"5829_CR20","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30(21):2654\u201363.","journal-title":"J Clin Oncol"},{"key":"5829_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1158\/1078-0432.CCR-14-1816","volume":"21","author":"Q Zhong","year":"2015","unstructured":"Zhong Q, Peng HL, Zhao X, Zhang L, Hwang WT. Effects of BRCA1- BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin Cancer Res. 2015;21:211\u201320.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"5829_CR22","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.cancergen.2015.05.031","volume":"208","author":"A Kwong","year":"2015","unstructured":"Kwong A, Chen J, Shin VY, Ho JC, Law FB, Au CH, et al. The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer. Cancer Genet. 2015;208(9):448\u201354.","journal-title":"Cancer Genet"},{"issue":"12","key":"5829_CR23","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/gim.2016.29","volume":"18","author":"E D'Andrea","year":"2016","unstructured":"D'Andrea E, Marzuillo C, De Vito C, Di Marco M, Pitini E, Vacchio MR, et al. Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations. Genet Med. 2016;18(12):1171\u201380.","journal-title":"Genet Med"},{"issue":"27","key":"5829_CR24","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.1200\/JCO.2010.28.0719","volume":"28","author":"JS Kwon","year":"2010","unstructured":"Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, et al. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol. 2010;28(27):4214\u201320.","journal-title":"J Clin Oncol"},{"issue":"3","key":"5829_CR25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12687-016-0266-4","volume":"7","author":"I Slade","year":"2016","unstructured":"Slade I, Hanson H, George A, Kohut K, Strydom A, Wordsworth S, et al. A cost analysis of cancer genetic service model in the UK. J Community Genet. 2016;7(3):185\u201394.","journal-title":"J Community Genet"},{"issue":"4","key":"5829_CR26","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jval.2017.01.004","volume":"20","author":"A Eccleston","year":"2017","unstructured":"Eccleston A, Bentley A, Strydom A, Vereecken W, George A, Rahman N. A cost-effectiveness evaluation of germline BRCA1 and BRCA2 testing in UK women with ovarian Cancer. Value Health. 2017;20(4):567\u201376.","journal-title":"Value Health"},{"issue":"26","key":"5829_CR27","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance Olaparib in patients with newly diagnosed advanced ovarian Cancer. N Engl J Med. 2018;379(26):2495\u2013505.","journal-title":"N Engl J Med"},{"key":"5829_CR28","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208447lbl.pdf"},{"issue":"10","key":"5829_CR29","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1080\/14737140.2018.1510323","volume":"18","author":"J Stewart","year":"2018","unstructured":"Stewart J, George A, Banerjee S. Olaparib for the treatment of relapsed ovarian cancer with a BRCA1\/2 mutation. Expert Rev Anticancer Ther. 2018;18(10):947\u201358.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"10106","key":"5829_CR30","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949\u201361.","journal-title":"Lancet."},{"key":"5829_CR31","doi-asserted-by":"crossref","unstructured":"Tan DSP, Kaye SB. Chemotherapy for patients with BRCA1\/2- mutated ovarian cancer: same or different? ASCO Educational Book; 2015. p. 114\u201321. \n                    Asco.org\/edbook","DOI":"10.14694\/EdBook_AM.2015.35.114"},{"issue":"9","key":"5829_CR32","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/jmedgenet-2018-105472","volume":"55","author":"JM McCuaig","year":"2018","unstructured":"McCuaig JM, Stockley TL, Shaw P, Fung-Kee-Fung M, Altman AD, Bentley J, et al. BRCA to Community of Practice. Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a canadian multisociety roadmap. J Med Genet. 2018;55(9):571\u20137.","journal-title":"J Med Genet"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5829-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5829-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5829-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T23:23:42Z","timestamp":1593213822000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5829-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,28]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5829"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5829-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,28]]},"assertion":[{"value":"3 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All study subjects provided written, informed consent to participate in the study approved by Ethics Committee (Song H et al., 2014). The present Project was approved by IAB of IRCCS-Istituto tumori G Paolo II Bari, Italy.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"641"}}